[ad_1]
Dozens of Romanian COVID-19 patients participated in a clinical study and received experimental treatment with this drug, and their medical condition improved significantly. The study was conducted at the “Matei Balş” Institute, in October this year.
“I think it is the medicine of the moment. It is a targeted drug and be careful, this is the first time we have talked about a new drug. The other variants of antiviral therapy, as we well know, were not new variants. They were also used in others. viral infections, “said Adrian Marinescu, an infectious disease doctor at the Matei Balş Institute in the capital, according to observator.ro
Treatment with Regeneron consists of the administration of two synthetic antibodies, a copy of those produced naturally by the body, which help the body fight infection.
“It just came to our knowledge then. Why? Because it prevents the virus from entering the cell. As long as it fails to enter, which if it did, the changes are continuous, the efficiency is minimal,” Adrian Marinescu also explained.
According to him, the cocktail should be administered in the first week after the onset of symptoms and cannot be used in patients who need oxygen or in intensive care. The drug can be used successfully to treat mild to moderate forms of the disease. Clinical studies show that treatment reduces viral load and protects patients who receive it from developing severe forms of the disease.
The first patient treated with Regeneron
The president of the United States, Donald Trump, was the first to publicly praise the treatment, during the period in which he was infected with Sars-CoV-2.
“It just came to our notice then. And it was amazing. I felt good right away. For me, it was not a therapeutic drug. It just cured me. I call this a cure,” Donald Trump said.
The Americans have authorized the emergency use of Regeneron therapy, but it is not known when the treatment will be approved for use in Europe.
